http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008058355-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dc98eb67b6d75e60ec6622c1ab825c3b |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-155 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-33 |
| filingDate | 2007-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_45beca325741ee33c47c0ea359c53637 |
| publicationDate | 2009-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2008058355-A3 |
| titleOfInvention | Descriptive report of patent of invention of the medicament 'atorvastatin + metformin' in combined form for cardiovascular diseases |
| abstract | The patent of invention of the medicament 'atorvastatin + metformina' in combined form for cardiovascular diseases, is abridged to combination of two medicaments used against the cardiovascular diseases which are main causes of death in globalized world. There are neat correlation between the ponderal again and the weight excess with risk of cardiovascular illness. The weight excess predisposes to these ilnesses due to abnormalities in the metabolism of the lipids, glucose and arterial pressure. The resistance to insulin/ hyperinsulinemia seems to be an risk factors independent risk factors associated as the obesity, hyperlipedemia and hypertension, either in men or in women. The insulin and the growth factors similar to insulin estimulate activity of the smooth muscle cells and are involved in the atherogenese and even in the reestenosis that follows to coronary repair by the angiosplasty. Other insulin effects are related to the mechanisms that contribute for the development either of the hypertension or of the dyslipidemia. The patent of invention of the medicament' atorvastatin + metformin' in combined form for cardiovascular diseases, diminishes the insulin resistance, arterial pressure, ponderal again and improves the lipidic profile of these patients, reducing so much the probability of cardiovascular events and consequently the death of this sort. |
| priorityDate | 2006-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 20.